The estimated Net Worth of Sarah Gheuens is at least $3.68 Миллион dollars as of 1 July 2024. Dr Gheuens owns over 8,375 units of Agios Pharmaceuticals Inc stock worth over $2,102,111 and over the last 3 years he sold AGIO stock worth over $0. In addition, he makes $1,573,525 as Chief Medical Officer at Agios Pharmaceuticals Inc.
Dr has made over 13 trades of the Agios Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 8,375 units of AGIO stock worth $371,096 on 1 July 2024.
The largest trade he's ever made was exercising 9,375 units of Agios Pharmaceuticals Inc stock on 23 December 2022 worth over $415,406. On average, Dr trades about 3,823 units every 63 days since 2021. As of 1 July 2024 he still owns at least 47,441 units of Agios Pharmaceuticals Inc stock.
You can see the complete history of Dr Gheuens stock trades at the bottom of the page.
Dr. Sarah Gheuens M.D., Ph.D. is the Chief Medical Officer at Agios Pharmaceuticals Inc.
As the Chief Medical Officer of Agios Pharmaceuticals Inc, the total compensation of Dr D at Agios Pharmaceuticals Inc is $1,573,525. There are 4 executives at Agios Pharmaceuticals Inc getting paid more, with Jacqualyn Fouse having the highest compensation of $16,608,000.
Dr D is 41, he's been the Chief Medical Officer of Agios Pharmaceuticals Inc since . There are 21 older and 2 younger executives at Agios Pharmaceuticals Inc. The oldest executive at Agios Pharmaceuticals Inc is Dr. Tak Wah Mak, 75, who is the Co-Founder & Member of Scientific Advisory Board.
Over the last 11 years, insiders at Agios Pharmaceuticals Inc have traded over $77,887,085 worth of Agios Pharmaceuticals Inc stock and bought 3,229,562 units worth $154,554,190 . The most active insiders traders include Kevin P Starr, Robert Nelsen и John Maraganore. On average, Agios Pharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $765,588. The most recent stock trade was executed by Rahul D. Ballal on 11 August 2024, trading 2,302 units of AGIO stock currently worth $102,002.
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Agios Pharmaceuticals Inc executives and other stock owners filed with the SEC include: